Research
Print page
Switch language
The Capital Region of Denmark
- a part of Copenhagen University Hospital
Published
Effect of ruboxistaurin (RBX) On visual acuity decline over a 6-year period with cessation and reinstitution of therapy: results of an open-label extension of the Protein Kinase C Diabetic Retinopathy Study 2 (PKC-DRS2)
Research output: Contribution to journal › Journal article › Research › peer-review
The PKC-DRS2 was a Phase 3, randomized, double-masked, placebo (PBO)-controlled, 3-year study of the effect of 32 mg/day of ruboxistaurin (RBX), an orally administered protein kinase C inhibitor, on vision loss in patients with moderate to severe nonproliferative diabetic retinopathy. Ruboxistaurin reduced the occurrence of sustained moderate visual loss (SMVL; ≥15-letter decline in visual acuity sustained for the last 6 months of study participation) from 9.1% in the PBO group (N = 340) to 5.5% in the RBX group (N = 345, P = 0.034). This study evaluates the primary end point of SMVL in a 2-year open-label extension (OLE) of the PKC-DRS2, which began a median of 466 days (range, 263-1,296 days) after the conclusion of PKC-DRS2.
| Original language | English |
|---|---|
| Journal | Retina |
| Volume | 31 |
| Issue number | 6 |
| Pages (from-to) | 1053-9 |
| Number of pages | 7 |
| ISSN | 0275-004X |
| DOIs | |
| Publication status | Published - 2011 |
- Administration, Oral, Diabetic Retinopathy, Double-Blind Method, Enzyme Inhibitors, Female, Humans, Indoles, Male, Maleimides, Middle Aged, Protein Kinase C, Retreatment, Vision Disorders, Vision Tests, Visual Acuity, Withholding Treatment
Research areas
ID: 34572754